Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6481-6488

  Gross, Thomas G ^a   Bucuvalas, John C ^a   Park, Julie R ^a   Greiner, Timothy C ^a   Hinrich, Steven H ^a   Kaufman, Stuart S ^a   Langnas, Alan N ^a   McDonald, Ruth A ^a   Ryckman, Frederick C ^a   Shaw, Byers W ^a   Sudan, Debra L ^a   Lynch, James C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; PREDNISONE; RITUXIMAB; ANTINEOPLASTIC AGENT; METHOTREXATE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DEATH; DISEASE COURSE; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; SURVIVAL; TREATMENT FAILURE; TREATMENT RESPONSE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; GRAFT SURVIVAL; INFANT; ISOLATION AND PURIFICATION; METHODOLOGY; MULTICENTER STUDY; PRESCHOOL CHILD; PROBABILITY; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; ORGAN TRANSPLANTATION; PREDNISONE; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27244449778     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.074     Document Type: Article

References (38)

1. Paya CV, Fung JJ, Nalesnik MA, et al: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders: ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517-1525, 1999
2. Swerdlow AJ, Higgins CD, Hunt BJ, et al: Risk of lymphoid neoplasia after cardiothoracic transplantation. Transplantation 69:897-904, 2000
3. Ho M, Jaffe R, Miller G, et al: The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45:719-727, 1988
4. Opelz G, Dohler B: Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4:222-230, 2004
5. Hayashi RJ, Kraus MD, Patel AL, et al: Posttransplant lymphoproliferative disease in children: Correlation of histology to clinical behavior. J Pediatr Hematol Oncol 23:14-18, 2001
6. Praghakaran K, Wise B, Chen A, et al: Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 34:112-116, 1999
7. Smets F, Vajro P, Cornu G, et al: Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 69: 982-984, 2000
8. Suryanarayan K, Natkunam Y, Berry G, et al: Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation. J Pediatr Hematol Oncol 23:452-455, 2001
9. Watts RG, Hilliard LM, Berkow RL: Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation. J Pediatr Hematol Oncol 24:622-626, 2002
10. Leblond V, Dhedin N, Mamzer Bruneel M-F, et al: Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 19:772-778, 2001
11. Garret TJ, Chadburn A, Barr ML, et al: Posttransplant lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone. Cancer 72:2782-2785, 1993
12. Morrison VA, Dunn DL, Manivel JC, et al: Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 97:14-24, 1994
13. Swinnen LJ, Mullen GM, Carr TJ, et al: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86:3333-3340, 1995
14. Leblond V, Sutton L, Dorent R, et al: Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 13:961-968, 1995
15. Colleoni GWB, Oliveira JSR, Borducchi DMM, et al: Post-transplant lymphoproliferative disorders (PTLD) after renal transplantation: Management and evolution of seven cases among 1002 renal transplants in Sao Paulo, Brazil. Leuk Lymphoma 39:145-150, 2000
16. Gerstenkom C, Jackson G, Di Franco F, et al: Outcome of PTLD in renal and liver allograft recipients. Transplant Proc 33:2469-2472, 2001
17. Leblond V, Davi F, Charlotte F, et al: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 16:2052-2059, 1998
18. Dotti G, Fiocchi R, Motta T, et al: Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney and liver transplant. Transplantation 69:827-833, 2000
19. Mamzer-Bruneel M-F, Lome C, Morelon E, et al: Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 18:3622-3632, 2000
20. Davis CL, Wood BL, Sabath DE, et al: Interferon-alfa treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 66:1770-1779, 1998
21. Liebowitz D, Anasti J, Hagos F, et al: Posttransplant lymphoproliferative disorders (PTLD): Clinicopathologic characterization and response to immunomodulatory therapy with interferon-alpha. Ann Oncol 7:28, 1996 (abstr)
22. Shapiro RS, Chauvenet A, McGuire W, et al: Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med 318:1334, 1988
23. Benkerrou M, Jais JP, Leblond V, et al: Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 92:3137-3147, 1998
24. Milpied N, Vasseur B, Parquet N, et al: Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 11:113-116, 2000 (suppl 1)
25. Choquet S, Herbrecht R, Socie G, et al: Multicenter, open label, phase II trial to evaluate the efficacy and safety of treatment with rituximab in patients suffering from B-cell post-transplantation lymphoproliferative disorders (B-PTLD) (M39037 trial). Ann Oncol 13:37, 2002 (abstr)
26. Gross TG, Hinrichs SH, Winner J, et al: Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low dose chemotherapy. Ann Oncol 9:339-340, 1998
27. Gross TG: Low-dose chemotherapy for children with post-transplant lymphoproliferative disease, in Oertel SH, Riess H (eds): Recent Results in Cancer Research. Berlin-Heidelberg, Germany, Springer-Verlag, 2002, pp 96-103
28. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 12:3835-3849, 1999
29. Collins MH, Montone KT, Leahey AM, et al: Post-transplant lymphoproliferative disease in children. Pediatr Transplant 4:250-257, 2001
30. Gross TG, Steinbuch M, DeFor T, et al: B cell lymphoproliferative disorder following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 23:251-258, 1999
31. Murphy SB: Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980
32. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860-1861, 1971
33. Trofe J, Buell JF, Beebe TM, et al: Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience. Am J Transplant 5:775-780, 2005
34. Buell JF, Gross TG, Hanaway MJ, et al: Chemotherapy for posttransplant lymphoproliferative disorder: The Israel Penn International Transplant Tumor Registry Experience. Transplant Proc 37:956-957, 2005
35. Oertel SHK, Zeidler K, Grefer J, et al: Monotherapy with anti-CD20 antibody rituximab (Ritux) in patients with post-transplant lymphoproliferative disease (PTLD): Results of a multicentre phase II study. Blood 100:573a, 2002 (abstr 2250)
36. Buell JF, Gross TG, Hanaway MJ, et al: Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement. Proc Transplant 37:954-955, 2005
37. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
38. Orjuela M, Gross TG, Cheung Y-K, et al: A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone and rituximab) (CPR) in patients with post-transplant lymphoproliferative disorder (PTLD) following solid organ transplant (SOT). Clin Cancer Res 9:39455-39525, 2003 (suppl)